Literature DB >> 9130710

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

D Graus-Porta1, R R Beerli, J M Daly, N E Hynes.   

Abstract

We have analyzed ErbB receptor interplay induced by the epidermal growth factor (EGF)-related peptides in cell lines naturally expressing the four ErbB receptors. Down-regulation of cell surface ErbB-1 or ErbB-2 by intracellular expression of specific antibodies has allowed us to delineate the role of these receptors during signaling elicited by: EGF and heparin binding EGF (HB-EGF), ligands of ErbB-1; betacellulin (BTC), a ligand of ErbB-1 and ErbB-4; and neu differentiation factor (NDF), a ligand of ErbB-3 and ErbB-4. Ligand-induced ErbB receptor heterodimerization follows a strict hierarchy and ErbB-2 is the preferred heterodimerization partner of all ErbB proteins. NDF-activated ErbB-3 or ErbB-4 heterodimerize with ErbB-1 only when no ErbB-2 is available. If all ErbB receptors are present, NDF receptors preferentially dimerize with ErbB-2. Furthermore, EGF- and BTC-induced activation of ErbB-3 is impaired in the absence of ErbB-2, suggesting that ErbB-2 has a role in the lateral transmission of signals between other ErbB receptors. Finally, ErbB-1 activated by all EGF-related peptides (EGF, HB-EGF, BTC and NDF) couples to SHC, whereas only ErbB-1 activated by its own ligands associates with and phosphorylates Cbl. These results provide the first biochemical evidence that a given ErbB receptor has distinct signaling properties depending on its dimerization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130710      PMCID: PMC1169769          DOI: 10.1093/emboj/16.7.1647

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

Review 2.  Oncogenes, growth factors, and signal transduction.

Authors:  B J Druker; H J Mamon; T M Roberts
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

3.  The primary structure of epidermal growth factor.

Authors:  C R Savage; T Inagami; S Cohen
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

4.  Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation.

Authors:  D Taverna; B Groner; N E Hynes
Journal:  Cell Growth Differ       Date:  1991-03

5.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.

Authors:  G D Plowman; G S Whitney; M G Neubauer; J M Green; V L McDonald; G J Todaro; M Shoyab
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Overexpression of the c-erbB-2 protein in human breast tumor cell lines.

Authors:  N E Hynes; H A Gerber; S Saurer; B Groner
Journal:  J Cell Biochem       Date:  1989-02       Impact factor: 4.429

7.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Authors:  P P Di Fiore; O Segatto; W G Taylor; S A Aaronson; J H Pierce
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

8.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

9.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

10.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Authors:  C Wallasch; F U Weiss; G Niederfellner; B Jallal; W Issing; A Ullrich
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  390 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

Review 2.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 3.  Neuregulin signaling via erbB receptor assemblies in the nervous system.

Authors:  Sean Murphy; Randy Krainock; Muly Tham
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

4.  Intracellular signals that control cell proliferation in mammalian balance epithelia: key roles for phosphatidylinositol-3 kinase, mammalian target of rapamycin, and S6 kinases in preference to calcium, protein kinase C, and mitogen-activated protein kinase.

Authors:  M Montcouquiol; J T Corwin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 5.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

6.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

7.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 8.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 9.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

10.  S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling.

Authors:  Chengshan Xu; Hongyan Chen; Xiang Wang; Jidong Gao; Yiqun Che; Yi Li; Fang Ding; Aiping Luo; Shuguang Zhang; Zhihua Liu
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.